Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Antiplatelet Therapy and Cardiovascular Diseases, Acute Myocardial Infarction Research, Coronary Interventions and Diagnostics, and Atrial Fibrillation Management and Outcomes.
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial
Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction
One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trial
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease